Conditions: Physician Education
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 23
Healthy volunteers: no

Brief summary:
Randomized trial to evaluate impact of healthcare provider( clinician and nursing staff) support and education on treatment discontinuation rates in the absence of progression in patients with metastatic colorectal cancer treated with regorafenib. Intensified education and support will be provided through an application for iPad which has automatic links to grading, dose reduction and side effect management ,as well as, references for additional articles.

Detailed description:

Arms:
arm 1: Investigators were supported with enhanced drug-specific information via an iPad application (SMART). arm 2: Investigators were supported with standard prescribing information.

Interventions: intervention 1: Regorafenib (Stivarga, BAY73-4506) intervention 2: iPAD application intervention 3: Bayer specialist
Intervention descriptions: intervention 1: Dose(s) 160 mg tablet (4 tablets per day at 40 mg) daily for 3 weeks on / 1 week off intervention 2: Investigators were supported with enhanced drug-specific information via an iPad application (SMART). intervention 3: The treating investigator will have access to the prescribing information and have ability to consult a Bayer specialist, should questions arise.

Protocol document: